Skip to main content
MedicHelpLine
Join Free
Verified Professional Network190+ CountriesHIPAA-Aware Platform
Back to Drug Index
General MedicationsORALGeneric

LETROZOLE;VRIBOCICLIB SUCCINATE

LETROZOLE;RIBOCICLIB SUCCINATE

Standard Dose
200MG;2.5MG
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: None (Tentative Approval)
Summary

Approval overview LETROZOLE;VRIBOCICLIB SUCCINATE is listed in Drugs@FDA under application 215975 (ANDA).

Review priority: STANDARD Marketing status: None (Tentative Approval) Active ingredient LETROZOLE;RIBOCICLIB SUCCINATE Form and strength TABLET;ORAL - 200MG;2.5MG Sponsor MSN LABS PVT LTD Submission history Latest submission status date: 2023-05-01 00:00:00.

Structured Monograph

Clinical summary

Approval overview LETROZOLE;VRIBOCICLIB SUCCINATE is listed in Drugs@FDA under application 215975 (ANDA). Review priority: STANDARD Marketing status: None (Tentative Approval) Active ingredient LETROZOLE;RIBOCICLIB SUCCINATE Form and strength TABLET;ORAL - 200MG;2.5MG Sponsor MSN LABS PVT LTD Submission history Latest submission status date: 2023-05-01 00:00:00. Submission type: ORIG.

Monitoring

  • • Marketing status: None (Tentative Approval)
  • • Review priority: STANDARD

Interaction Notes

  • No interaction notes stored yet.
LETROZOLE;VRIBOCICLIB SUCCINATE (LETROZOLE;RIBOCICLIB SUCCINATE) | Drug Monograph | MedicHelpline